25 research outputs found
Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study
Full text linkPrimary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs)
Get PDFAbstract not available
42-month follow-up of sonidegib efficacy and safety in advanced basal cell carcinoma: Final analysis from BOLT.
No full textEffects of sonidegib dose reduction or delay in locally advanced basal cell carcinoma: 42-month data from BOLT.
No full textSonidegib improved quality of life in patients with advanced basal cell carcinoma: results from the phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment trial through 73 weeks
No full textInternational audienc
Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC)
No full textLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.
No full textVismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
No full textEfficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.
No full textRecommended from our members
Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC)
No full text
